Effect of impeller rotational phase on the FDA blood pump velocity fields

Abstract

AbstractBackgroundThe Food and Drug Administration (FDA) blood pump is an open‐source benchmark cardiovascular device introduced for validating computational and experimental performance analysis tools. The time‐resolved velocity field for the whole impeller has not been established, as is undertaken in this particle image velocimetry (PIV) study. The level of instantaneous velocity fluctuations is important, to assess the flow‐induced rotor vibrations which may contribute to the total blood damage.MethodsTo document these factors, time‐resolved two‐dimensional PIV experiments were performed that were precisely phase‐locked with the impeller rotation angle. The velocity fields in the impeller and in the volute conformed with the previous single blade passage experiments of literature.ResultsDepending on the impeller orientation, present experiments showed that volute outlet nozzle flow can fluctuate up to 34% during impeller rotation, with a maximum standard experimental uncertainty of 2.2%. Likewise, the flow fields in each impeller passage also altered in average 33.5%. Considerably different vortex patterns were observed for different blade passages, with the largest vortical structures reaching an average core radii of 7 mm. The constant volute area employed in the FDA pump design contributes to the observed velocity imbalance, as illustrated in our velocity measurements.ConclusionsBy introducing the impeller orientation parameter for the nozzle flow, this study considers the possible uncertainties influencing pump flow. Expanding the available literature data, analysis of inter‐blade relative velocity fields is provided here for the first‐time to the best of our knowledge. Consequently, our research fills a critical knowledge gap in the understanding of the flow dynamics of an important benchmark cardiovascular device. This study prompts the need for improved hydrodynamic designs and optimized devices to be used as benchmark test devices, to build more confidence and safety in future ventricular assist device performance assessment studies.